The large capital raise signals extended runway for clinical development but introduces substantial near-term dilution. The 40% conversion premium suggests management confidence in future stock appreciation, but the size of the offering—combined with recent insider selling—may pressure shares short-term. Traders should monitor use of proceeds and clinical trial milestones as forward catalysts.
Price Chart
Executive Summary
Revolution Medicines announced the pricing of concurrent public offerings: 10.56M shares of common stock at $142.00 per share, raising $1.5B gross, and $500M in 0.50% convertible senior notes due 2033, increasing both offerings from previously announced sizes. Net proceeds are expected to total approximately $1.92B ($1.435B from stock, $486.8M from notes), to be used for R&D, commercialization, and general corporate purposes.
Key Financial Metrics
Key Facts
- Priced concurrent offerings: $1.5B common stock offering and $500M convertible note offering
- Common stock priced at $142.00 per share; 10,563,381 shares issued
- Convertible notes have 0.50% coupon, mature May 1, 2033, with $500M principal
- Offering sizes increased from initial $750M (stock) and $250M (notes)
- Underwriters granted 30-day option to purchase up to 1,584,506 additional shares
- Initial conversion price for notes: ~$198.80 per share (40% premium to stock offering price)
- Net proceeds estimated at $1.435B (stock) and $486.8M (notes), totaling ~$1.92B
- Proceeds to fund R&D, commercialization, and general corporate expenses
- Recent insider selling: $3.1M across 8 transactions in past 30 days
Financial Impact
Approximately $1.92B in net proceeds, but significant dilution from equity raise and potential conversion of notes
Risk Factors
- Significant equity dilution from $1.5B common stock offering
- Potential for future share overhang if convertible notes are equity-settled
- Market may interpret large capital raise as lack of confidence in near-term commercial viability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3274107 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.54 (+5.42%) |
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.54 (+5.42%) |
Sep 15, 2026 17d ago | Insider Cluster | $204.86 $190.95 | ▼ −6.79% | ▼ −7.61% | $206.54 (+0.82%) |
Sep 14, 2026 17d ago | Insider Cluster | $204.86 $192.86 | ▼ −5.86% | ▼ −7.98% | $206.54 (+0.82%) |
Aug 26, 2026 5w ago | 8-K | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.54 (−4.13%) |
Aug 26, 2026 5w ago | Press Release | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.54 (−4.13%) |
Aug 25, 2026 5w ago | Insider Cluster | $211.38 $209.87 | ▼ −0.71% | ▼ −0.18% | $206.54 (−2.29%) |
Jul 2, 2026 13w ago | Press Release | $189.24 $191.13 | ▲ +1.00% | ▲ +0.07% | $206.54 (+9.14%) |
Jul 1, 2026 13w ago | Insider Cluster | $187.51 $190.46 | ▲ +1.57% | ▲ +1.31% | $206.54 (+10.15%) |
Jun 22, 2026 14w ago | 8-K | $165.81 $192.62 | ▲ +16.17% | ▲ +16.62% | $206.54 (+24.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access